Member Info for LTbeliever

@Maidit
Hate to be a spoilsport but as per DVRG's RNS 5 days ago, it will probably need a few more months for validation by the EU authorities:
"The Microtox® BT equipment was also re-designed to deliver a portable, mobile testing unit to process breath tests at point of care. The established test protocols have been carried out at Labskin from test subjects provided by the Royal College of Surgeons in Ireland for the early prototype and secured positive results. Regulatory approvals for human diagnostic equipment is evaluated on test equipment that will be used on humans. Therefore, roll out of the breath test is subject to meeting the satisfactory requirements of EU Regulatory approvals which will be carried out on the latest version of the Microtox® BT units. Further information on this will be provided in H1 2022."

BUT, if and when we get the EU stamp of approval, the impact on the SP should be significant because the target market will be GLOBAL.

RB,
For what it's worth, 2019's Trading Update:
https://www.lse.co.uk/rns/MSYS/pre-close-trading-update-7oemsp3ngs957ym.html

RB,
Within the next 4 weeks (by mid-Jan) we should have a 2021 Trading update; you will have your answers then :)

just earlier posted on DVRG's board (and Twitter):
"Provided a company is within the parameters of 'market expectation' it does not require any additional statement, even if no guidance is given". This suggests a broker note for all future revenues IS market expectation for AIM purposes, even if it is only company broker note. It is entirely up to the company to issue a statement that contradicts market expectations.

The above refers to DVRG's expected 24mln 2022 Revenue i.e. GJB is telling us that it is a realistic figure; For MSYS this would mean, if achieved by DVRG, potential sales (just originating via DVRG) of 2-4 mln!!! (assuming 10-20%, which I think is very conservative).
Now, if you add the Chinese TDM (20 units?) i.e. 1-2 million, plus Bioprocessing xx(unknown), plus 500k-1mln service/consumables, we could have sales of:
MIN 4mln
MAX 6-7mln ??
Sounds crazy?? I just want to show the potential in 2022; if above is achieved, this means Breakeven by Y/E 2022.

RB,
I think we are past 1mln already, maybe looking at 600-700k for H2; we had 2 RNS re sales via DVRG, which probably add up to 400-450k, plus ongoing service fees and consumable sales in H2; I reckon (extrapolating from H1) 25-50k and 200-250k respectively.

BTW NU,
I saw your posts over on DVRG board - if 2022 Revenue for DVRG really hits +20mln, that means a minimum of 2-3 mln for MSYS (as it will be mostly coming from Microtox PDs and BTs), don't you think?

NU,
needs cash for Xmas shopping maybe?? :)
No news flow since the Interims, other than DVRG-related; China Distributor deal pending for 8 months, I wonder if it's delayed due to covid, or something else; or will be something big (wishful thinking!) ?

PC,
We just need to be patient for another 6 months; a lot will happen IMHO during H1 2022.

Interview?? Noooo, let Glenn conclude with the Chinese, no need to distract him :)

NU,
It's almost Y/E, less than 10 trading days left; the Placees who want to lock their 2021 profit are using every opportunity to sell down, and this is usually when good news is announced as volumes go up.
FED meets on Wednesday too, so there is some tredipation.
With each new RNS, we get proof that MSYS is moving closer to profitability (in 2023 probably) so, even if people sell, it's just more opportunity for us to average down (which I am doing whenever I get cash).
Still waiting on China and Bioprocessing deals, in situ cancer diagnosis' developments, Digital Health GPs, many water monitoring trials WILL conclude in Q1 and so forth;
Do you see or expect anything negative (MSYS-specific) in the next 3-6 months? I personally expect only good news.
If USA tech stocks crash (the current fear in the market), this will only make growing minnows such as MSYS more attractive (once the last short term Placees sell out).
GLA

Consumables and Services - ongoing and rising;
And remember that these kind of sales, although higher margin than equipment sales, will not necessarily be flagged through an RNS henceforth because they will be for lower amounts than lumpy equip. sales, but continuous, recurring and growing month by month. So, we will be able to analyse the breakdown probably only every 6 months i.e. at interims and annual reporting.

Max19,
We could easily have another 200-300k order from China in the next few weeks (before Febr. 1, the Chinese New Year) upon the signing of the agrmnt with our China Distributor.

This figure is 50% of H1 Revenues, and it seems the way things are going, 35-40% of expected H2 ones; so it's quite realistic to expect a full Year 2021 Revenue of well over 1 million, an all time record.
A very upbeat trading update in the next 4 weeks would not be a surprise IMHO

https://www.lse.co.uk/rns/MSYS/further-order-from-deepverge-bectzynsntq6kft.html

This shows what money is being spent on orders to MSYS in preparation for the Q1 launch of the MWMS.

PC,

You can start from here (I'm not LTB for nothing!).

https://www.lse.co.uk/rns/MSYS/global-collaboration-agreement-with-axcend-corp-4mqayzhn8qg03v2.html

Glenn is back! :)
"Microsaic (AIM: MSYS), is pleased to announce that it has received a further order from DeepVerge plc ("DeepVerge") for additional miniaturised mass spectrometry ("MS") equipment and services (the "Order"). The value of the Order is approximately £262k and part of the order (the "Further Order") is being fulfilled pursuant to the Company's existing Framework Services Agreement.
Additionally, the Order includes a number of units of Microsaic's newly developed solid phase extraction - liquid chromatography ("SPE-LC") Systems, which do not form part of the Agreement, and related consumables which will be used for quality and contamination detection in a range of markets including water and soil analysis (the "New Order").
The New Order has an approximate value of £153k and comprises the additional SPE-LC Systems and related consumables"

So, 2/3 of the order relate to non-standard equipment and consumables, i.e. a) with a higher profit margin b) future repeatability.
VERY POSITIVE!

PC,
MSYS will be sharing monthly revenues once this service is up and running; as soon as a utility, local authority etc subscribe to the service, the others will have to follow suit fairly quickly.IMHO
"MWMS is positioned as a critical new component in the armoury of national and provincial government response protocol. It allows utilities to extend their reach into smaller sites for more granular ‘last mile’ surveillance, enabling local authorities and private companies to protect citizens and customers by monitoring for COVID and a range of additional pathogens, including forever chemicals."

Something else for Q1 is the completion of the various PD trials; at least for 1 (the "secret" government one) it will be at Feb. end, meaning probably an RNS sometime in March 2022. The others in China-India were announced earlier actually so maybe completion will be in Jan-Feb. the latest?

Plus, Glenn mentioned in the Interims Pres. that the Distributor would be announced "SOON".

They have announced the Mnfcing co; the Distributor will in effect represent MSYS in China, and not only. So why would it be a secret?

NU,
Also, note that the Distributor bought MSYS' equipment back in May so it has been "playing" with it for the last 6 months!